Latest Breaking News On - European summary - Page 11 : comparemela.com

Galapagos NV: Galapagos initiates Phase 3 program with filgotinib in patients with active axial spondyloarthritis

OLINGUITO Phase 3 program in adults with axial spondyloarthritis (AxSpA) to include two parallel studies to investigate the efficacy and safety of filgotinib in patients with active radiographic AxSpA

Nordrhein westfalenRegion flamandeUnited kingdomNorthern irelandGreat britainVan gijselMarieke vermeerschDaniele dambrosioXenofon baraliakosElisa chenaillerSandra cauwenberghsEuropean unionJapanese ministry of healthUniversity bochumExchange commissionEuropean medicines agency

Investegate |Galapagos NV Announcements | Galapagos NV: Galapagos initiates Phase 3 program with filgotinib in patients with active axial spondyloarthritis

Investegate announcements from Galapagos NV, Galapagos initiates Phase 3 program with filgotinib in patients with active axial spondyloarthritis

Nordrhein westfalenUnited kingdomRegion flamandeNorthern irelandGreat britainVan gijselDaniele dambrosioMarieke vermeerschXenofon baraliakosElisa chenaillerSandra cauwenberghsPercentage of participants achieving spondyloarthritis international societyEuropean unionJapanese ministry of healthGilead sciences incUniversity bochum

Galapagos initiates Phase 3 program with filgotinib in patients with active axial spondyloarthritis

Galapagos initiates Phase 3 program with filgotinib in patients with active axial spondyloarthritis
finanzen.ch - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.ch Daily Mail and Mail on Sunday newspapers.

United kingdomRegion flamandeNordrhein westfalenNorthern irelandGreat britainElisa chenaillerVan gijselSandra cauwenberghsDaniele dambrosioMarieke vermeerschXenofon baraliakosPercentage of participants achieving spondyloarthritis international societyEuropean unionJapanese ministry of healthEuropean medicines agencyGilead sciences inc

Akebia Receives European Commission Approval for Vafseo™ (vadadustat) for the Treatment of Symptomatic Anaemia Associated with Chronic Kidney Disease in Adults on Chronic Maintenance Dialysis

Akebia Receives European Commission Approval for Vafseo™ (vadadustat) for the Treatment of Symptomatic Anaemia Associated with Chronic Kidney Disease in Adults on Chronic Maintenance Dialysis
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomMercedes carrascoJohnp butlerJohn butlerPrnewsfoto akebia therapeutics incAkebia therapeutics incDrug administrationEuropean medicines agencyEuropean commissionEuropean unionExchange commissionAkebia therapeuticsChief executive officerMedicinal productsHuman use

Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy

Recommendation for approval based on Phase 3 TRANSFORM study, supporting the potential of Breyanzi in earlier lines of therapy in this patient population . | March 31, 2023

United kingdomBristol myers squibbAnne kerberEuropean medicines agencyBristol myers squibb companyCell therapy developmentCommittee for medicinal products human useDrug administrationEuropean commissionEuropean unionMedicinal productsHuman useBristol myersMyers squibbCentralized marketing authorizationGreat britain